Purpose: To determine the maximum tolerated dose or maximal administered dose and pharmacokinetic and safety profiles of s.c. administered vascular endothelial growth factor Trap (aflibercept), a novel antiangiogenic agent.
Many malignancies depend on the formation and maintenance of a blood supply for tumor growth, invasion, and metastasis, which is known as tumor neoangiogenesis. The most clinically relevant proangiogenic factors is the vascular endothelial growth factor (VEGF), which is produced by most solid tumors, and whose expression has been shown to inversely correlate with clinical outcome (1) . VEGF binds to and activates at least two receptors, Flt-1 (VEGFR1) and Flk-1 (VEGFR2), which are predominantly located on the vascular endothelium. VEGF is a powerful mitogen for endothelial cells, thus promoting the formation of new vessels that are required for normal and neoplastic tissue growth. In addition, VEGF potently increases vessel permeability.
A variety of agents are being developed to target the inhibition of VEGF, VEGF receptor binding, VEGF receptor tyrosine kinase activity, and downstream effectors. The use of anti-VEGF agents has recently been validated in the clinic. For example, the humanized anti-VEGF monoclonal antibody bevacizumab (Avastin, Genentech) has been approved for the treatment of advanced metastatic colorectal, lung, and breast cancer, showing a prolongation in progression-free survival and/or survival when added to various chemotherapy regimens (2) (3) (4) .
Aflibercept (AVE0005, VEGF Trap; Regeneron Pharmaceuticals and sanofi-aventis Pharmaceuticals) is a specific antagonist that binds and inactivates circulating VEGF in the blood stream and in the extravascular space (5) . Aflibercept is a fusion protein and soluble recombinant decoy VEGF receptor composed of Domain 2 of VEGFR1 and Domain 3 of VEGFR2 fused to the Fc of IgG1. It contains all human amino acid sequences and blocks all VEGF-A isoforms and placental growth factor (P1GF). Aflibercept binds VEGF with a dissociation constant (KD) of ∼0.5 pmol/L, an ∼800-fold increase in affinity compared with bevacizumab, which has a K D in the order of 0.1 to 10 nmol/L for the VEGF ligand (6) .
Preclinical studies have shown that aflibercept has antiangiogenic activity and can cause both tumor growth inhibition and regression in several mouse xenograft models (5, (7) (8) (9) . Treatment with aflibercept resulted in tumors that were largely avascular as visualized by staining with antibodies to platelet endothelial cell adhesion molecule (7) . Nascent tumor vasculature disappeared rapidly, and vessels that could be identified within the tumor appeared to be co-opted host vessels. In preclinical models, an excess of free aflibercept versus complex is required to maintain levels of free VEGF as low as possible, with a target ratio of 1:1. Rudge and colleagues (10) showed that as the dose of aflibercept is increased, the tumor size regresses, until a plateau is reach at ∼5 mg/kg. Preclinical studies revealed potential toxicities associated with aflibercept to be similar to effects observed in preclinical studies with anti-VEGF monoclonal antibodies (11) .
We now report the first clinical trial of aflibercept conducted in patients with solid tumors. The primary objective of this phase 1 study was to determine a range of relatively safe and well-tolerated doses of s.c. administered aflibercept. The subcutaneous formulation is being studied to improve tolerability and convenience for patients. Secondary objectives included an evaluation of the pharmacokinetics, potential immunogenicity, and biological effect on tumor growth.
Patients and Methods

Study design and treatment levels
This was a multicenter, open-label, sequential-cohort, doseescalation, phase 1 study of s.c. administered aflibercept to patients with relapsed or refractory, progressive solid tumor for whom there were no curative treatment options available.
The initial cohort of three patients was dosed with 25 μg/kg aflibercept administered s.c. After the patients were observed for a 4-wk period to evaluate the pharmacokinetics of aflibercept, dosing resumed in these same patients with a series of six weekly injections at the same dose level. Patients with stable or responding disease by Response Evaluation Criteria in Solid Tumors criteria after 10 wk were eligible to continue to receive aflibercept at the same dose and schedule (until the time of disease progression) in a follow-on extension study. Intrapatient dose escalation was not allowed.
Sequential dose level cohorts of three to six patients were to be enrolled, receiving aflibercept injections of 50, 100, 200, 400, and 800 μg/kg weekly and 800 μg/kg twice weekly, following the same pattern of single followed by repeated dose administration. Administration of >800 μg/kg as a single dose was considered impractical due to volume considerations imposed by the 25-mg/mL drug concentration of the formulation. Injecting more then two vials was considered not feasible.
VEGF concentrations in the sera of cancer patients have been reported to be in the picograms/milliliter range and aflibercept shows antitumor efficacy in murine models at serum concentrations above 4 μg/mL. Based on allometric scaling from animal studies, steady-state serum concentrations of aflibercept in humans were estimated to range from 0.6 μg/mL (25 μg/kg weekly) to 13 μg/mL (800 μg/kg weekly). Thus, the proposed dose escalation of aflibercept was expected to achieve serum levels in excess of circulating VEGF levels reported in cancer patients as well as exceed the concentrations associated with preclinical studies.
The maximum tolerated dose (MTD) for aflibercept was defined as the dose level below, which two of six patients exhibited a dose-limiting toxicity (DLT). The protocol called for an expansion cohort of five additional patients to be enrolled at either the maximum administered dose (MAD) reached or the MTD, whichever was lower.
Definition of DLT
Adverse events reports were collected at each study visit. Adverse event severity was rated according to the National Cancer Institute Common Toxicity Criteria (CTC) version 2.0. DLT was defined as any new CTC grade 3 or 4 toxicity considered at least possibly drug related and which occurred within the 10-wk study period.
Proteinuria and hypertension were two types of adverse events considered of special interest (2, (12) (13) (14) (15) (16) . If a patient developed CTC (v2) grade 2 or greater proteinuria on routine urinalysis, the spot urine protein to creatinine ratio (17) was evaluated. If the urine protein to creatinine ratio was >3, a 24-h urine collection was done for quantification of urine protein and creatinine, dosing was halted, and nephrology consultation was initiated. For the purpose of this study, grade 3 hypertension that could be easily controlled with a single antihypertensive agent or with
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Patient selection
Eligible patients were required to have a diagnosis of advanced solid tumor malignancy with no known curative therapy with at least one measurable site of disease. Laboratory requirements included hemoglobin of ≥9 g/dL, WBC count of ≥3,000/mm 3 , absolute neutrophil count of ≥1,500/mm 3 , platelets of ≥100,000/mm 3 , serum bilirubin of ≤1.5 times the institutional upper limit of normal (ULN), aspartate aminotransferase and alanine aminotransferase of ≤2.5 times the ULN (≤4 ULN if liver metastases were present), and serum creatinine of ≤1.5 times ULN (or a creatinine clearance of >60 mL/min). Exclusion criteria included the following: Eastern Cooperative Oncology Group performance status of >3; central nervous system metastases; receipt of an investigational drug, chemotherapy, radiation therapy, or biological therapy within 3 wk before study day 1; use of the following medications: erythropoietin, granulocyte, or granulocyte macrophage colony-stimulating factor, cyclooxygenase-2 inhibitors, corticosteroids, and systemic hormonal contraceptive agents. The centers' Institutional Review Boards (IRB) approved the study, and written informed consent was obtained from all patients. Patients were enrolled at Memorial Sloan-Kettering Cancer Center, Yale University Cancer Center, and the University of Arizona Cancer Center.
Treatment assessment
Safety. Baseline assessment included a physical examination, review of systems, complete blood count with differential and platelet count, hepatic and renal functions tests, coagulation parameters, urine analysis, 12-lead electrocardiogram, chest X-ray, and computed tomography (CT) or magnetic resonance imaging (MRI) scan of the brain. Negative pregnancy test (human chorionic gonadotropin in urine or blood) was required in women of childbearing potential. Measurement of visible and palpable tumors, chest X-ray, CT, scans or MRIs (as clinically indicated) were done at baseline. During the study, history, and physical examination results, weight, vital signs, Karnofsky score, complete blood count, blood chemistry, urinalysis, and urine protein to creatinine ratio (18) were monitored weekly.
Efficacy. Radiographic evaluation (CT, MRI, or chest X-ray) was used to assess response to treatment. A whole-body (chest/abdomen/pelvis) CT scan was done at study entry to identify anatomical sites of tumor involvement. Estimates of tumor burden were made by study site radiologists according to RECIST criteria (19) .
Pharmacokinetic study
Plasma samples were drawn for analysis of circulating aflibercept levels before the first dose of study drug and 1, 2, 4, 8, 24, 30, 48, 72, 120, and 168 h after dose and on days 15, 22, 29, 36, 43, 50, 57, 64, 71, and 92. The 800 μg/kg twice weekly dose level cohort had additional blood sampling on days 11 and 32. Pharmacokinetic parameter estimates, including C max , T max , AUC, Cl/F, Vss, and MRT for both free aflibercept and VEGF-aflibercept complexes ("bound aflibercept"), were derived from data acquired after the initial dose of study drug using WinNonlin (PharSight Corporation). Plasma aflibercept levels taken 1 wk following the final dose were taken as representative of presumed steady-state levels during chronic administration. Pharmacokinetic parameters were not estimated for the 1,600 mg/kg/wk dose group, since the total weekly dose was achieved using two doses of 800 μg/kg.
Serum samples were obtained (before treatment and on Ddys 22, 43, and 57, and then tested quarterly thereafter) to be assayed for the presence of antiaflibercept antibodies. The proportion of patients developing such antibodies was evaluated for each dose level cohort.
Assay methods. Free aflibercept (not bound to VEGF) was quantified from plasma by binding it to human VEGF165 adsorbed to the surface of a polystyrene solid support. A match-paired secondary mouse monoclonal antibody, specific to epitopes on the VEGFR1 domain of the Trap, was bound to the complex, and an enzyme-linked antibody (peroxidase-conjugated Affinipure goat anti-mouse IgG Fc-γ) was then bound to the immobilized mouse monoclonal complex. A substrate solution was added to achieve color intensity that was directly proportional to the amount of free aflibercept. Finally, the enzymatic reaction was terminated with 1M phosphoric acid, and the resultant light absorbance was read at 450 to 570 nm. The mean baseline response from blank samples was subtracted from all other readings, and absorbance readings of the standard samples were calibrated against their respective nominal concentrations using the Log-Log regression model from which all other readings were subsequently calculated. The range of the assay was from 3.13 to 100 ng/mL of free aflibercept with a lower limit of quantitation of 31.3 ng/mL of free aflibercept in the sample.
VEGF-aflibercept complex was quantified in plasma using a direct ELISA method by binding hVEGF165-VEGF complexes to antihuman VEGF165 antibody adsorbed to the surface of a polystyrene solid support. Similar steps to those described above for the quantification of free aflibercept were followed to quantify the amount of bound aflibercept. The range of the assay was from 8.78 to 100 ng/mL of bound aflibercept with a lower limit of quantitation of 43.9 ng/mL of bound aflibercept in the sample.
Quantification of total aflibercept in plasma was determined by adding the adjusted bound aflibercept level to the corresponding free aflibercept level at a given time point.
Antiaflibercept antibodies were quantified in serum using an ELISA method whereby aflibercept was coated onto a microplate surface. The calibrators, controls, and serum samples from patients treated with aflibercept were added to the microtiter plate, thus binding reactive antibodies to the immobilized aflibercept molecule. After incubation and washing away unbound material, a peroxidase-conjugated antibody [mouse anti-human IgG, F(ab')2 fragment specific] was added to the wells of the microplate to bind the immobilized human antibodies. After washing away the unbound conjugate, the peroxidase substrate 3,3′,5,5′-tetramethylbenzadine was added to achieve color intensity. The substrate reaction was terminated by the addition of 1M phosphoric acid, and light absorbance was read at 450-570 nm. The reaction response was reported in terms of equivalent RF IUs per milliliter (IU/Ml). The data generated by the software application SoftMax Pro were reviewed, and for positive samples, only the values within the range of the standard curve were accepted and incorporated into this report. The range of the assay was from 263.4 to 3,000 microIU/Ml, with a lower limit of quantitation of 52.7 IU/Ml in the sample.
Western blot detection of VEGF-A bound to aflibercept in clinical samples
To show the binding of aflibercept to VEGF in patient plasma, 0.5 mL aliquots of plasma from a single patient before aflibercept treatment (predose) and after injection of 50 μg/kg were subjected to Western blot analysis.
Six micrograms of a biotinylated mouse monoclonal antibody with high specificity to the aflibercept was added to each patient sample. After 1 h of incubation at room temperature, immunoprecipitation was done using 25 mL of immobilized NeutrAvidin beads (Pierce), which was added to the samples and incubated overnight at 4°C. Beads were pelleted and washed five times with 1 mL of PBS. Twentyfive microliters of nonreducing SDS-PAGE sample loading buffer was added to the beads, and samples were heated at 1,000°C for 5 min. The samples were subjected to gel electrophoresis on a 4% to 20% TRIS-glycine gel (Novex).
Following electrophoresis, the gel was transferred onto a polyvinylidene difluoride membrane. Following transfer, the membrane was blocked with 5% bovien serum albumin (Fluka) in TBS + 0.1% Tween 20 for 1 h at room temperature. The membrane was probed with a mouse monoclonal antibody that specifically recognizes hVEGF-A isoforms (mab-293, R + D Systems) at 0.2 μg/mL in 2.5% bovien serum albumin in TBS + 0.1% Tween 20 for 1 h at room temperature. The membrane then was washed five times with TBS + 0.1% Tween 20 over 20 min, after which the membrane was then incubated with a goat anti-mouse IgG-horseradish peroxidase-conjugated antibody (Pierce) at 0.05 μg/mL in TBS + 0.1% Tween 20 for 1 h at room temperature. The Western blot was developed using enhanced chemiluminescence detection (Amersham).
Statistical methods
Statistical analyses and summaries of patient data were done in SAS version 8.0 (SAS Institute). Inferential testing was not done.
Results
Patient characteristics. Thirty-eight patients (19 men and 19 women) were enrolled at three centers. Patient characteristics are presented in Table 1 . Eleven patients (29%) had an Eastern Cooperative Oncology Group performance status of 0; the remaining 27 patients (71%) had a performance status of 1. The median number of prior chemotherapy regimens was 5 (range, 1-9). The most frequent histologies were renal cell carcinoma (9), colon adenocarcinoma (6), and lung adenocarcinoma (4).
Doses of aflibercept administered. Table 2 shows the number of patients treated per dose level and the number of total doses administered per dose level. Three patients were added to the 100, 400, and 800 μg/kg weekly dose level cohorts in accordance with the protocol that called for patients to be added in the event a DLT was observed. One additional patient was added to each of the 50, 200, and 800 μg/kg weekly dose level cohorts to replace patients who withdrew from the study before beginning the weekly dosing phase. Because the MTD was not 
reached, the patients in the expansion cohort were treated at the MAD (800 μg/kg twice weekly). Twenty-eight patients (74%) completed the 10-week study period, and 18 (47%) entered the extension phase with stable disease. Nine patients (24%) completed 6 months on study. Two patients (13%) at dose levels of 800 μg/kg/week or biweekly completed at least 12 months on study, and 1 patient with medullary thyroid carcinoma has maintained stable disease for 44 months. Of the 18 patients entering the extension phase, 9 patients were from the lower dose cohorts (39% in the 25 to 400 μg/kg/week dose levels) and 9 from the higher dose cohorts (60% in the 800 μg/kg once or twice weekly dose levels).
DLT, MAD, and MTD. The MTD was not reached. The MAD level was 800 μg/kg/s.c./twice weekly. This dose was defined as the MAD as further dose escalations were not possible due to solubility and dose limits associated with this subcutaneous formulation. Four definitively or possibly drug-related DLTs occurred (Table 2) . One patient (100 μg/kg) developed confusion and 3 days of decreased oral intake. An MRI of the brain revealed a small area of ischemia. The patient was admitted and received i.v. hydration. Her mental status improved and a followup MRI scan revealed resolution of the ischemic area. One patient (400 μg/kg) developed grade 3 proteinuria, which resolved with study drug discontinuation. A renal biopsy was done, revealing changes consistent with minimal change glomerulonephritis. As this patient was also taking large doses of a cyclooxygenase-2 inhibitor, the renal dysfunction and biopsy changes could not be definitively attributed to aflibercept alone. One patient (800 μg/kg) with heavily pretreated head and neck cancer developed grade 3 leukopenia after receiving one dose of aflibercept, which resolved to baseline after study drug discontinuation.
Finally, 1 patient (800 μg/kg twice weekly) was diagnosed with pulmonary embolism. This pulmonary embolism was treated with anticoagulation. This pulmonary embolism was subsequently identified on the baseline CT scan obtained before aflibercept administration.
The other grade 3 drug-related adverse events documented were hypertension and proteinuria. Adverse events that appeared only at the higher (400 μg/kg/week and above) dose levels included hoarseness and grade 3 hypertension. The latter resolved with oral antihypertensive agents. In all, six patients (19%) receiving aflibercept doses of ≥100 mc/kg/week developed new or worsened hypertension. Proteinuria did not seem to exhibit a dose-dependent increase in frequency or severity in this study.
Non-DLT. A total of 95 drug-related adverse events occurred during the 10-week study period, listed by frequency in Table 3 . Sixty-seven events (71%) were grade 1; 21 events (22%) were grade 2; 6 events (6%) were grade 3; and 1 event (1%) was grade 4.
Three patients (one patient at each dose level: 400, 800, and 1,600 μg/kg/wk) experienced grade 3 hypertension requiring treatment with one or two antihypertensive agents. Injection site-related adverse events were infrequent. The dose-related adverse events were hypertension, hoarseness, and anorexia. Other than mild proteinuria, no significant pattern of laboratory changes was observed. Renal function as assessed by serum blood urea nitrogen and creatinine measurements remained unaffected throughout the study.
Pharmacokinetics. The pharmacokinetic profile of aflibercept was characterized by measuring plasma levels of both free aflibercept and aflibercept bound to VEGF. Table 4 presents the pharmacokinetics of aflibercept at the seven dose levels in this study. Free aflibercept concentrations peaked between 0.3 and 3 days following the first dose and ranged from an average of 45 ng/mL after the initial 50 μg/kg dose, to 3,031 ng/mL after a dose of 800 μg/kg (free aflibercept could not be detected in the 25 μg/kg dose level cohort), and increased slightly more than proportionally with dose thereafter, with a mean C max of 3.0 ± 1.5 μg/mL reached at the 800 μg/kg dose level. Free aflibercept had a relatively short half-life (<1 to 3 days) compared with the bound form, which had an apparent elimination half-life of ∼18 days, indicating that aflibercept is rapidly converted into the complex in the circulation. Free aflibercept accumulated in plasma, and after 6 weeks of repeated dosing at the 800 μg/kg dose level, trough-free aflibercept levels averaged about 7,400 ng/mL. In contrast to free aflibercept, levels of VEGF-aflibercept complex did not increase strictly in proportion to dose, with a mean C max of 1.4 ± 0.2 μg/mL at the 800 μg/kg dose level, and the amount of circulating bound aflibercept at steady-state remained relatively constant above the 400 μg/kg dose level at ∼2,000 to 3,000 μg/mL. Also, the plasma concentrations of free aflibercept increased rapidly in proportion to dose beyond the 400 μg/kg dose level, on average reaching ∼7,000 μg/mL at the end of the study.
Formation of the complex appeared to saturate; levels of VEGF-aflibercept complex seen after the first dose did not increase appreciably between the 800 μg/kg weekly and twice weekly dose levels. Plasma-bound aflibercept concentrations peaked between 3.5 and 9 days. Figure 1 represents the relationship between mean free, bound, and total aflibercept at week 16 of the study.
Presumed steady-state (C last ) concentrations of bound aflibercept did not substantially increase between the 400 and 800 μg/kg once and twice weekly dose levels, remaining fairly constant at 2.2 ± 0.7, 2.8 ± 0.9, and 2.8 ± 1.2 μg/mL, at each of these dose level cohorts, respectively. The apparent saturation of aflibercept binding suggests that much of the VEGF produced by the patients at these doses was being captured. Conversely, there was a disproportionate increase in both C max and C last for free aflibercept between the 400 and the 800 μg/kg dose levels. Only in the 800 μg/kg once weekly (5.1 ± 1.4 μg/mL versus 2.8 ± 0.9 μg/mL) and twice weekly (7.4 ± 5.0 μg/mL versus 2.9 ± 1.2 μg/mL) dose levels were average free aflibercept levels in excess of VEGF-aflibercept complex levels at the end of 6 weeks of repeated dosing. This phenomenon results from relatively rapid conversion of free aflibercept to bound aflibercept as it forms a complex with VEGF at the lower dose levels up to the point at which the availability of VEGF becomes rate limiting.
The elimination half-life of free aflibercept increased with increasing dose from 1.7 ± 0.2 days at the 50 μg/kg dose level to 3.4 ± 0.8 days at the 800 μg/kg dose level. The elimination half-life of VEGF-aflibercept complex, on the other hand, was relatively consistent, and was estimated to be about 18 days in the 25 μg/kg through 400μg/kg dose levels. However, the 4-week pharmacokinetic sampling period of the study was not of sufficient duration to permit acquisition of a sufficient number of time points to support estimation of the elimination phase for bound aflibercept at the highest dose level (800 μg/kg, twice weekly).
Western blot detection of VEGF-A bound to aflibercept in clinical samples. Western blot analysis detected binding of aflibercept to both major circulating isoforms of VEGF, VEGF165, and VEGF121 in 8-week posttreatment, but not pretreatment, samples of the single patient studied (Fig. 2) , indicating that aflibercept actively binds to its target in vivo.
Antitumor activity. Twenty-eight patients (74%) completed the 10-week study, and 18 (47%) entered the extension study. Ten patients failed to complete the study either due to adverse events (two patients) or to disease progression or disease-related symptoms (eight patients). The proportion of patients completing the study with stable disease was highest (9 of 11; 82%) among patients who completed all 6 weeks of the repeated dosing portion of the study at the 800 μg/kg once and twice weekly dose levels, compared with 9 (53%) of 17 who received all doses and completed the study at or below the 400 μg/kg dose level. When patients who did not receive the entire planned course of study drug administration are considered, 9 (60%) of 15 patients in the 800 μg/kg once and twice weekly dose group maintained stable disease, compared with 9 (40%) of 23 in the lower dose level cohorts.
Twenty (53%) of the 38 patients maintained stable disease for a minimum of 1 month; 2 patients had stable disease for >1 year. One patient had a minor response: a 35-year-old woman with multiple treatment-resistant advanced-stage bronchoalveolar carcinoma who continued aflibercept treatment at the 800 μg/kg twice weekly dose level in the extension study had a radiographic and clinical response to aflibercept treatment, with cavitation of multiple lung lesions and improvement in consolidation of her nearly opacified left lung, which was maintained for 26 months. Another patient, a 67-year-old male with thyroid cancer maintained stable disease for 44 months at a dose of 800 μg/kg weekly.
Discussion
VEGF Trap represents a novel therapeutic approach for the treatment of patients with cancer. Aflibercept is a circulating decoy receptor that has been engineered by fusing portions of the high affinity extracellular domains from human VEGFR1 and human VEGFR2 to the Fc region of a human IgG1 molecule. This construct gives aflibercept broad affinity for all ligands that bind to the two main VEGF receptors, including all isoforms of VEGF-A, VEGF-B, as well as PlGF. Furthermore, aflibercept has affinity for VEGF-A that is 800-fold higher than that reported for bevacizumab, a humanized mouse monoclonal antibody (6) . The potential clinical benefit of this property is currently unknown.
In this study, we have shown that subcutaneous aflibercept has an acceptable safety profile. Ninety-three percent of the drug-related adverse events were grade 1 and 2 in severity, and only 7% were grade 3 or 4. Dose-related adverse events were hypertension, hoarseness, and anorexia, but no dose-related pattern of serious adverse events were identified. The MTD was not reached within the range of dose levels studied. Adverse events of particular interest included proteinuria, hypertension, and hoarseness, all of which have been previously reported in studies of other VEGF-targeting agents (2-4, 15) .
Although not the primary study end point, there was a suggestion of a dose-response in antitumor effect, since more patients enrolled in the highest dose level cohorts (at or above 800 μg/kg/weekly) maintained stable disease by Response Evaluation Criteria in Solid Tumors criteria than did those treated at the lower dose levels. Among patients in the higher dose level cohorts, there appeared to be a correlation between steady-state levels of VEGFbound aflibercept at the end of the study and the inhibition of tumor growth as reflected in the Response Evaluation Criteria in Solid Tumors sum of longest diameters of target tumor lesions.
Aflibercept is found in the circulation of patients in two forms: "free" aflibercept (not bound to VEGF), and "bound" aflibercept (in 1:1 complex with VEGF). Free aflibercept is available to bind to VEGF in the circulation and in the tissues. The complex reflects the amount of VEGF produced in the body that has been bound and presumably neutralized. Aflibercept showed clear binding of VEGF in the circulation of patients treated with the drug, as shown by both ELISA and by Western blot. The half-life of total aflibercept in plasma is ∼18 days when administered s.c., which is similar to the half-life of therapeutic antibodies (10) . As previously observed, there is rapid saturation of aflibercept binding in humans, with plateau reached in all patients treated.
With targeted therapy such as aflibercept, other parameters are often needed to determine the correct dose of the drug in the phase 2 or 3 setting. The results of further studies that are ongoing using i.v. administration (20) will be required before a recommended phase 2 dose can be determined.
In this study, there is strong evidence that doses of aflibercept administered s.c. to patients with advanced solid tumors are tolerable and can provide disease stability at or above 800 μg/kg/week. This assertion is based on: (a) the favorable safety profile of aflibercept at 800 μg/kg/week or biweekly; (b) evidence of saturation of circulating VEGF in patients treated at these dose levels; (c) evidence of free aflibercept above the minimum target efficacy exposure determined in preclinical studies; (d) higher rates of stable disease for heavily pretreated patients at these dose levels than at lower dose levels; and (e) evidence of more prolonged stable disease at these dose levels.
VEGF inhibitors such as bevacizumab, sunitinib, and sorafenib have recently fulfilled the promise of antiangiogenic therapy in patients with cancer. Aflibercept potentially represents the next generation of VEGF ligand binders with higher affinity for the target and broader affinity for more therapeutic targets. Based on the favorable safety profile and the evidence of clinical benefit noted in this study, additional clinical studies with aflibercept, using either i.v. administration or an improved subcutaneous formulation, both as a single agent and in combination with other anticancer drugs, are in progress.
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